Sepsis - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 297
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S107D2E0A5EEN
Leaflet:

Download PDF Leaflet

Sepsis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H2 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 12, 5, 1, 62, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 19 and 7 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents
Introduction
Sepsis - Overview
Sepsis - Therapeutics Development
Sepsis - Therapeutics Assessment
Sepsis - Companies Involved in Therapeutics Development
Sepsis - Drug Profiles
Sepsis - Dormant Projects
Sepsis - Discontinued Products
Sepsis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Sepsis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Sepsis - Pipeline by Adrenomed AG, H2 2017
Sepsis - Pipeline by Am-Pharma BV, H2 2017
Sepsis - Pipeline by Arch Biopartners Inc, H2 2017
Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
Sepsis - Pipeline by Asahi Kasei Pharma Corp, H2 2017
Sepsis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Sepsis - Pipeline by Batu Biologics Inc, H2 2017
Sepsis - Pipeline by Biomedica Management Corp, H2 2017
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Sepsis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2017
Sepsis - Pipeline by Chiome Bioscience Inc, H2 2017
Sepsis - Pipeline by Cilian AG, H2 2017
Sepsis - Pipeline by Commence Bio Inc, H2 2017
Sepsis - Pipeline by DoNatur GmbH, H2 2017
Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H2 2017
Sepsis - Pipeline by Endacea Inc, H2 2017
Sepsis - Pipeline by Evec Inc, H2 2017
Sepsis - Pipeline by Ferring International Center SA, H2 2017
Sepsis - Pipeline by Huons Co Ltd, H2 2017
Sepsis - Pipeline by Immune Response BioPharma Inc, H2 2017
Sepsis - Pipeline by Immunwork Inc, H2 2017
Sepsis - Pipeline by InflaRx GmbH, H2 2017
Sepsis - Pipeline by Integrated BioTherapeutics Inc, H2 2017
Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2017
Sepsis - Pipeline by Leading BioSciences Inc, H2 2017
Sepsis - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Sepsis - Pipeline by Merck & Co Inc, H2 2017
Sepsis - Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017
Sepsis - Pipeline by Navigen Inc, H2 2017
Sepsis - Pipeline by Nohla Therapeutics Inc, H2 2017
Sepsis - Pipeline by Novartis AG, H2 2017
Sepsis - Pipeline by Octapharma AG, H2 2017
Sepsis - Pipeline by OncoImmune Inc, H2 2017
Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Sepsis - Pipeline by Opsona Therapeutics Ltd, H2 2017
Sepsis - Pipeline by Peptinov SAS, H2 2017
Sepsis - Pipeline by ProThera Biologics Inc, H2 2017
Sepsis - Pipeline by Ra Pharmaceuticals Inc, H2 2017
Sepsis - Pipeline by Recce Ltd, H2 2017
Sepsis - Pipeline by Ribomic Inc, H2 2017
Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H2 2017
Sepsis - Pipeline by SetLance srl, H2 2017
Sepsis - Pipeline by Shionogi & Co Ltd, H2 2017
Sepsis - Pipeline by Sirtex Medical Ltd, H2 2017
Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Sepsis - Pipeline by Spider Biotech, H2 2017
Sepsis - Pipeline by Syntiron LLC, H2 2017
Sepsis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Sepsis - Pipeline by Therakind Ltd, H2 2017
Sepsis - Pipeline by Therashock LLC, H2 2017
Sepsis - Pipeline by TiGenix NV, H2 2017
Sepsis - Pipeline by Vascular BioSciences, H2 2017
Sepsis - Pipeline by ViiV Healthcare Ltd, H2 2017
Sepsis - Dormant Projects, H2 2017
Sepsis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Sepsis - Dormant Projects, H2 2017 (Contd..2), H2 2017
Sepsis - Dormant Projects, H2 2017 (Contd..3), H2 2017
Sepsis - Dormant Projects, H2 2017 (Contd..4), H2 2017
Sepsis - Discontinued Products, H2 2017
Sepsis - Discontinued Products, H2 2017 (Contd..1), H2 2017

LIST OF FIGURES

Number of Products under Development for Sepsis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
Skip to top


OncoImmune, Inc. - Product Pipeline Review - 2015 US$ 1,275.00 Aug, 2015 · 24 pages
Cilian AG - Product Pipeline Review - 2015 US$ 1,275.00 May, 2015 · 26 pages
Hyperglycemia - Pipeline Review, H1 2014 US$ 1,700.00 Apr, 2014 · 38 pages

Ask Your Question

Sepsis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: